This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Heat shock protein 90 (Hsp90); Hsp70	*In vitro* studies identified an Hsp90 inhibitor that could help treat breast cancer. Hsp90 inhibitors that work by blocking the Hsp90 ATP-binding site can promote cancer cell survival through increased expression of Hsp70. In triple-negative breast cancer cells, a compound that blocked Hsp90's interaction with a cochaperone lowered Hsp70 expression, whereas a compound that blocked the Hsp90 ATP-binding site increased Hsp70 expression. The interaction inhibitor also increased cell-cycle arrest and apoptosis and decreased cell migration compared with a compound that blocked the Hsp90 ATP-binding site. Next steps could include testing the interaction inhibitor in mouse models of cancer. At least 13 companies have Hsp90 inhibitors in clinical and preclinical testing to treat cancer. ***SciBX*** **4(37); doi:10.1038/scibx.2011.1034** **Published online Sept. 22, 2011**	Findings unpatented; unavailable for licensing	Pimienta, G. *et al. Mol. Pharm.*; published online Sept. 1, 2011; doi:10.1021/mp200346y **Contact:** Genaro Pimienta, Yale University, New Haven, Conn. e-mail: genaro.pimienta-rosales@yale.edu